Exam 1

Question 1

1st line treatments for pancreatic adenocarcinoma (3 combos)

Answer 1

folfirinox vs gemcitabine
nab paclitaxel vs gemcitabine
cisplastin vs clinical trials

Question 2

PD-1 blockers

Answer 2

pembrolizumab (Keytruda)
nivolumab (Opdivo)
cemiplimab (Libtayo)

Question 3

PD-L1 blockers

Answer 3

atezolizumab (Tecentriq)
avelumab (Bavencio)
durvalumab (Imfinzi)

Question 4

CTLA-4 inhibitor

Answer 4

ipilimumab (Yervoy)

Question 5

BRAC1 targeted therapies

Answer 5

olaparib
niraparib
talazoparib
rucaparib

Question 6

KRAS targeted therapies

Answer 6

binimetinib
trametinib
cobimetinib

Question 7

synthetic lethality

Answer 7

PARP inhibitor treats BRCA1 cancers-
both PARP and BRCA1 pathways repair DNA -> in BRCA cancer PARP can still repair -> blocking PARP disrupts all repair

Question 8

KRAS activates RAF. RAF inhibitors:

Answer 8

vemurafenib
trametinib

Question 9

KRAS activates PI3K. PI3K inhibitors:

Answer 9

perifosine
idelalisib
copanlisib
duvelisib

Question 10

KRAS-G12C inhibitor

Answer 10

AMG 510

Question 11

CDK4 and CDK6 inhibitors:

Answer 11

palbociclib
ribociclib
abemaciclib

Question 12

combo for NRAS mutation treatment

Answer 12

ribociclib (Kisqali) + binimetinib (MEKTOVI)